Lombard Odier Asset Management Switzerland SA Buys Shares of 3,883 Regeneron Pharmaceuticals, Inc. $REGN

Lombard Odier Asset Management Switzerland SA bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the first quarter, HoldingsChannel reports. The institutional investor bought 3,883 shares of the biopharmaceutical company’s stock, valued at approximately $3,000,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Insigneo Advisory Services LLC increased its holdings in Regeneron Pharmaceuticals by 3.0% in the 4th quarter. Insigneo Advisory Services LLC now owns 445 shares of the biopharmaceutical company’s stock worth $343,000 after buying an additional 13 shares in the last quarter. Arjuna Capital boosted its holdings in shares of Regeneron Pharmaceuticals by 3.2% during the 1st quarter. Arjuna Capital now owns 457 shares of the biopharmaceutical company’s stock valued at $353,000 after acquiring an additional 14 shares during the last quarter. Guardian Wealth Advisors LLC NC grew its stake in shares of Regeneron Pharmaceuticals by 3.3% in the fourth quarter. Guardian Wealth Advisors LLC NC now owns 443 shares of the biopharmaceutical company’s stock worth $342,000 after acquiring an additional 14 shares during the period. TD Private Client Wealth LLC raised its holdings in shares of Regeneron Pharmaceuticals by 9.7% during the fourth quarter. TD Private Client Wealth LLC now owns 169 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 15 shares during the last quarter. Finally, MCF Advisors LLC lifted its position in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock valued at $35,000 after purchasing an additional 15 shares during the period. 83.31% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research analyst reports. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Cantor Fitzgerald cut their price objective on Regeneron Pharmaceuticals from $785.00 to $750.00 and set an “overweight” rating for the company in a report on Monday, July 6th. Leerink Partners reissued a “market perform” rating and issued a $641.00 target price (down from $792.00) on shares of Regeneron Pharmaceuticals in a report on Monday, May 18th. Citigroup downgraded Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $900.00 to $700.00 in a research note on Monday, May 18th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $787.88.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $656.01 on Monday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $821.11. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.96 and a current ratio of 3.57. The company has a market capitalization of $69.35 billion, a P/E ratio of 15.98, a P/E/G ratio of 1.45 and a beta of 0.24. The company has a fifty day moving average of $635.78 and a 200 day moving average of $714.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 EPS for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a return on equity of 13.16% and a net margin of 29.65%.The business had revenue of $3.61 billion for the quarter, compared to analysts’ expectations of $3.48 billion. During the same period last year, the firm earned $8.22 earnings per share. The business’s quarterly revenue was up 19.0% on a year-over-year basis. On average, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.12 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 4th. Investors of record on Wednesday, May 20th were given a dividend of $0.94 per share. The ex-dividend date was Wednesday, May 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 9.16%.

Insider Transactions at Regeneron Pharmaceuticals

In related news, Director Arthur F. Ryan sold 200 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the sale, the director owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. This trade represents a 1.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.97% of the company’s stock.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Analysts remain constructive ahead of Regeneron’s upcoming quarterly results, with one note saying the company is positioned to beat earnings expectations. Regeneron (REGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
• Positive Sentiment: Guggenheim raised its price target on Regeneron, signaling continued Wall Street confidence in the stock’s longer-term upside. Guggenheim Boosts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $1,000.00
• Neutral Sentiment: Multiple law firms are advertising deadlines and investor-rights notices related to the already-filed Regeneron securities class action, keeping the issue in the spotlight but not adding new allegations. The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit – REGN
• Neutral Sentiment: Additional firms, including Faruqi & Faruqi, Schall, and others, issued similar class-action reminders, which extends the legal-news flow around REGN. Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
• Negative Sentiment: Several lawsuits claim Regeneron misled investors about clinical-trial protocol and statistical risks, with one report citing a sharp selloff and an estimated $11 billion market-cap hit after the trial failure disclosure. Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial’s Protocol and Ultimate Failure – HBSS

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.